Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 3, 2008, Pages 347-359

  Brunati, Anna Maria ^a,c   Tibaldi, Elena ^a,c   Carraro, Amedeo ^a,c   Gringeri, Enrico ^b,c   D'Amico Jr , Francesco ^a,c   Toninello, Antonio ^a,c   Massimino, Maria Lina ^a,c   Pagano, Mario Angelo ^a,c   Nalesso, Giovanna ^a,c   Cillo, Umberto ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c CNR   (Italy)

Author keywords

Integrative signalling; PDGF receptor; PTX; S1P receptor

Indexed keywords

DIMETHYLSPHINGOSINE; FINGOLIMOD; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PTX; RECEPTOR BLOCKING AGENT; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; VPC 23019;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; LIVER CELL; LIVER FIBROSIS; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; IMMUNOLOGIC FACTORS; LIVER; LIVER CIRRHOSIS; LYSOPHOSPHOLIPIDS; MALE; PLATELET-DERIVED GROWTH FACTOR; PROPYLENE GLYCOLS; PROTEIN TRANSPORT; RATS; RATS, WISTAR; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 39149123166     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.11.008     Document Type: Article

References (52)

1. Bissell D.M. Hepatic fibrosis as wound repair: a progress report. J. Gastroenterol. 33 (1998) 295-302
2. Bissell D.M., Roulot D., and George J. Transforming growth factor beta and the liver. Hepatology 34 (2001) 859-867
3. Friedman S.L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328 (1993) 1828-1835
4. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275 (2000) 2247-2250
5. Friedman S.L. The virtuosity of hepatic stellate cells. Gastroenterology 117 (1999) 1244-1246
6. Rippe R.A., and Brenner D.A. From quiescence to activation: gene regulation in hepatic stellate cells. Gastroenterology 127 (2004) 1260-1262
7. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front. Biosci. 7 (2002) d1720-d1726
8. Win K.M., Charlotte F., Mallat A., Cherqui D., Martin N., Mavier P., Preaux A.M., Dhumeaux D., and Rosenbaum J. Mitogenic effect of transforming growth factor-b1 on human Ito cells in culture-evidence for mediation by endogenous platelet-derived growth factor. Hepatology 18 (1993) 137-145
9. Wong L., Yamasaki G., Johnson R.J., and Friedman S.L. Induction of b-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J. Clin. Invest. 94 (1994) 1563-1569
10. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., Caligiuri A., Pellegrini G., Ngo D.V., Romanelli R.G., and Gentilini P. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J Pathol. 148 (1996) 785-800
11. Hla T., Lee M.J., Ancellin N., Paik J.H., and Kluk M.J. Lysophospholipids-receptor revelations. Science 294 (2001) 1875-1878
12. Chun J., Goetzl E.J., Hla T., Igarashi Y., Lynch K.R., Moolenaar W., Pyne S., and Tigyi G. International Union of Pharmacology: XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54 (2002) 265-269
13. 3-mediated Akt activation and cross-talk with platelet-derived growth factor receptor (PDGFR). FASEB J. 18 (2004) 341-343
14. Tanimoto T., Lungu A.O., and Berk B.C. Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ. Res. 94 (2004) 1050-1058
15. 1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J. Biol. Chem. 279 (2004) 12300-12311
16. Milstien S., and Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell. 9 (2006) 148-150
17. Waters C., Pyne S., and Pyne N.J. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin. Cell. Dev. Biol. 15 (2004) 309-323
18. Pitson S.M., Xia P., Leclercq T.M., Moretti P.A., Zebol J.R., Lynn H.E., Wattenberg B.W., and Vadas M.A. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med. 201 (2005) 49-54
19. Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S., Caron M.G., Milstien S., and Spiegel S. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291 (2001) 1800-1803
20. Ikeda H., Yatomi Y., Yanase M., Satoh H., Maekawa H., Ogata I., Ozaki Y., Takuwa Y., Mochida S., and Fujiwara K. Biological activities of novel lipid mediator sphingosine 1-phosphate in rat hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G304-G310
21. 2 with Rho activation. Biochem. Biophys. Res. Commun. 320 (2004) 754-759
22. Aki F.T., and Kahan B.D. FTY720: a new kid on the block for transplant immunosuppression. Expert Opin. Biol. Ther. 3 (2003) 665-681
23. Virley D.J. Developing therapeutics for the treatment of multiple sclerosis. NeuroRx. 2 (2005) 638-649
24. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., Choudhury S., Skerjanec A., Kraus G., and Neumayer H.H. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13 (2002) 1073-1083
25. Gardell S.E., Dubin A.E., and Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol. Med. 12 (2006) 65-75
26. Massberg S., and Von Andrian U.H. Fingolimod and sphingosine-1-phosphate-modifiers of lymphocyte migration. N. Engl. J. Med. 355 (2006) 1088-1091
27. Yopp A.C., Ledgerwood L.G., Ochando J.C., and Bromberg J.S. Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin. Transplant 20 (2006) 788-795
28. Chiba K., Matsuyuki H., Maeda Y., and Sugahara K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell. Mol. Immunol. 3 (2006) 11-19
29. Graler M.H., and Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18 (2004) 551-553
30. Zhang X., Yu W.P., Gao L., Wei K.B., Ju J.L., and Xu J.Z. Effects of lipopolysaccharides stimulated Kupffer cells on activation of rat hepatic stellate cells. World J. Gastroenterol. 10 (2004) 610-613
31. Miyazaki T., Neff L., Tanaka S., Horne W.C., and Baron R. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J. Cell. Biol. 160 (2003) 709-718
32. Caligiuri A., De Franco R.M., Romanelli R.G., Gentilini A., Meucci M., Failli P., Mazzetti L., Rombouts K., Geerts A., Vanasia M., Gentilini P., Marra F., and Pinzani M. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124 (2003) 504-520
33. Gentilini A., Marra F., Gentilini P., and Pinzani M. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J. Hepatol. 32 (2000) 227-234
34. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., and Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278 (2003) 47408-47415
35. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., and Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554 (2003) 189-193
36. 2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol. Cell. Biol. 25 (2005) 4237-4249
37. Lee M.J., Van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R., Menzeleev R., Spiegel S., and Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-. Science 279 (1998) 1552-1555
38. Davis M.D., Clemens J.J., Macdonald T.L., and Lynch K.R. Sphingosine 1-phosphate analogs as receptor antagonist. J. Biol. Chem 28 (2005) 9833-9984
39. Edsall L.C., Van Brocklyn J.R., Cuvillier O., Kleuser B., and Spiegel S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37 (1998) 12892-12898
40. Liu H., Sugiura M., Nava V.E., Edsall L.C., Kono K., Poulton S., Milstien S., Kohama T., and Spiegel S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 275 (2000) 19513-19520
41. Kohama T., Olivera A., Edsall L., Nagiec M.M., Dickson R., and Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem. 273 (1998) 23722-23728
42. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., and Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427 (2004) 355-360
43. Tsukada S., Parsons C.J., and Rippe R.A. Mechanisms of liver fibrosis. Clin. Chim. Acta. 364 (2006) 33-60
44. Pinzani M., and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin. Liver Dis. 21 (2001) 397-416
45. Guma F.C.R., Mello T.G., Mermelstein C.S., Fortuna V.A., Wofchuk S.T., Gottfried C., Guaragna R.M., Costa M.L., and Borojevic R. Intermediate filaments modulation in an in vitro model of the hepatic stellate cell activation or conversion into the lipocyte phenotype. Biochem. Cell. Biol. 79 (2001) 409-417
46. Urata Y., Nishimura Y., Hirase T., and Yokoyama M. Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kobe J. Med. Sci. 51 (2005) 17-27
47. Hait N.C., Sarkar S., Le Stunff H., Mikami A., Maceyka M., Milstien S., and Spiegel S. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem. 280 (2005) 29462-29469
48. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., Rosenbach M., Hale J., Lynch C.L., Rupprecht K., Parsons W., and Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
49. Payne S.G., Oskeritzian C.A., Griffiths R., Subramanian P., Barbour S.E., Chalfant C.E., Milstien S., and Spiegel S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109 (2007) 1077-1085
50. Dudek S.M., Camp S.M., Chiang E.T., Singleton P.A., Usatyuk P.V., Zhao Y., Natarajan V., and Garcia J.G. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P(1) receptor. Cell Signal. 19 (2007) 1754-1764
51. Yasui H., Hideshima T., Raje N., Roccaro A.M., Shiraishi N., Kumar S., Hamasaki M., Ishitsuka K., Tai Y.T., Podar K., Catley L., Mitsiades C.S., Richardson P.G., Albert R., Brinkmann V., Chauhan D., and Anderson K.C. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 65 (2005) 7478-7484
52. Neviani P., Santhanam R., Oaks J.J., Eiring A.M., Notari M., Blaser B.W., Liu S., Trotta R., Muthusamy N., Gambacorti-Passerini C., Druker B.J., Cortes J., Marcucci G., Chen C.S., Verrills N.M., Roy D.C., Caligiuri M.A., Bloomfield C.D., Byrd J.C., and Perrotti D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117 (2007) 2408-2421